{"product_id":"akebia-marketing-mix","title":"Akebia Marketing Mix","description":"\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive analysis of Akebia's 4Ps: Product, Price, Place \u0026amp; Promotion, providing real-world examples. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eSimplifies the 4P's with clear categories for effortless brand positioning comprehension.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You Preview Is What You Download\u003c\/span\u003e\u003cbr\u003eAkebia 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe 4Ps Marketing Mix Analysis you see is exactly what you'll download instantly after purchasing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003ch2\u003e4P's Marketing Mix Analysis Template\u003c\/h2\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Snapshot—Get the Full Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAkebia's marketing success hinges on a strategic 4Ps mix. The product itself, innovative kidney treatments, meets a vital need. Their pricing, carefully structured, balances value and profitability. Distribution, leveraging specific channels, maximizes reach. Promotional efforts effectively communicate product benefits. \u003c\/p\u003e\n\u003cp\u003e Explore how Akebia's choices influence patient outcomes and market position. Unlock an in-depth 4Ps analysis to gain a deeper understanding of their approach. This report delivers insights, ready-to-use format for success. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVafseo (vadadustat)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVafseo (vadadustat) is Akebia's main product, an oral HIF-PH inhibitor. It's FDA-approved for anemia due to CKD in adults on dialysis. Vafseo boosts erythropoietin production, increasing hemoglobin. In 2024, Akebia's net product revenue from Vafseo was approximately $1.5 million. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOnce-Daily Oral Administration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVafseo's once-daily oral tablet formulation is a key marketing point. This feature addresses the need for patient convenience, potentially boosting adherence rates. For example, in 2024, oral medications showed an 80% adherence rate compared to 60% for injectables. This offers a competitive edge over injectable alternatives. This ease of use is vital for patients on dialysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePotential Label Expansion for Non-Dialysis Patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAkebia is considering expanding Vafseo's label to include non-dialysis CKD patients. Discussions with the FDA are ongoing, demonstrating proactive engagement. The VALOR Phase 3 trial is planned to evaluate vadadustat in this expanded patient group. This strategic move could significantly broaden Vafseo's market reach. As of Q1 2024, Akebia reported a net loss of $75.2 million.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial to Evaluate Three Times Weekly Dosing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAkebia's marketing strategy includes clinical trials like VOICE, a collaborative effort with U.S. Renal Care. This trial assesses Vafseo's safety and effectiveness when dosed thrice weekly, aligning with dialysis schedules. The study explores potential benefits and dosing flexibility for patients. The global dialysis market is projected to reach $103.6 billion by 2030. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eVOICE trial is evaluating Vafseo.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eIt focuses on thrice-weekly dosing.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThis aligns with hemodialysis.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThe trial explores additional benefits.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAddressing an Unmet Medical Need\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVafseo targets the unmet need for safer, oral anemia treatments in certain CKD patients. Akebia aims for Vafseo to become a new standard of care. The current market faces limitations in existing therapies. Vafseo's potential is supported by clinical trial data.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eVafseo addresses unmet medical needs in CKD anemia treatment.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eAkebia aims for Vafseo to be a new standard of care.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eExisting therapies have limitations.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eClinical data supports Vafseo's potential.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVafseo: A $103.6B Dialysis Market Opportunity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVafseo, Akebia's oral treatment, targets anemia in CKD patients on dialysis.  It’s designed for easier use, with potential label expansion. Clinical trials like VOICE boost Vafseo’s market potential.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eAspect\u003c\/th\u003e\n\u003cth\u003eDetails\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 Vafseo Revenue\u003c\/td\u003e\n\u003ctd\u003eApprox. $1.5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOral Med Adherence (2024)\u003c\/td\u003e\n\u003ctd\u003e80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDialysis Market (2030 Proj.)\u003c\/td\u003e\n\u003ctd\u003e$103.6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDistribution to Dialysis Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAkebia's distribution strategy centers on dialysis centers. They've established commercial supply agreements with major dialysis organizations. These agreements cover approximately 100% of U.S. dialysis patients. This focused approach ensures Vafseo's availability where it's most needed.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAuthorized Distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVafseo shipments started in January 2025, going to authorized distributors. This network likely includes wholesalers, ensuring dialysis centers get supplies. Akebia's strategy targets these distributors, vital for product reach. This approach supports Vafseo's launch, aiming to serve patients effectively. The focus on distribution highlights Akebia's market entry plan.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Contracting with Dialysis Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAkebia's regained U.S. rights to Vafseo. This allows direct contracting with dialysis organizations. This includes major providers and third-party centers. This strategy aims to boost market access and sales. In 2024, the dialysis market was valued at $77 billion. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAkebia's international strategy hinges on partnerships and licensing. Vafseo's approval across 37 countries demonstrates global ambitions. Collaborations with companies like Medice facilitate launches in European markets. These agreements are key to expanding Akebia's reach.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eVafseo is approved in 37 countries.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eMedice launched Vafseo in the U.K., Germany, Austria, and the Netherlands.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eLicensing agreements are central to international market penetration.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvailability Expected in January 2025\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eVafseo's U.S. market entry is anticipated for January 2025, a strategic move following its FDA approval in March 2024. Akebia actively prepared for this launch, with commercial activities gaining momentum. The expected availability is a critical step in the company's marketing strategy. This rollout aims to capitalize on the market opportunity for treating anemia. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eFDA approval in March 2024.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eCommercial launch activities pre-January 2025.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eMarket entry in January 2025.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eFocus on anemia treatment.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVafseo's Global Strategy: Dialysis Centers \u0026amp; Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAkebia’s Place strategy centers on delivering Vafseo to dialysis centers, crucial for anemia treatment. Distribution leverages commercial supply agreements and authorized distributors, maximizing patient access. International expansion uses partnerships like with Medice, enabling launches in key markets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct orange_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eAspect\u003c\/th\u003e\n\u003cth\u003eDetails\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. Launch\u003c\/td\u003e\n\u003ctd\u003eDirect-to-dialysis center focus.\u003c\/td\u003e\n\u003ctd\u003eFDA approval in March 2024.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistribution\u003c\/td\u003e\n\u003ctd\u003eCommercial supply agreements, distributors.\u003c\/td\u003e\n\u003ctd\u003eTarget: 100% of U.S. dialysis patients.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternational\u003c\/td\u003e\n\u003ctd\u003ePartnerships and licensing.\u003c\/td\u003e\n\u003ctd\u003eVafseo approval in 37 countries.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eromotion\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEngaging with Prescribers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAkebia's commercial team focuses on engaging nephrologists to boost Vafseo demand. Research indicates strong interest from nephrologists in prescribing Vafseo. In Q1 2024, Akebia reported $1.8 million in Vafseo net product revenue. This strategy aligns with the product's launch and market penetration goals. Engaging with prescribers is crucial for achieving sales targets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Affairs Team Activities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAkebia's medical affairs team is crucial for Vafseo's launch. They are establishing protocols for its use and sharing clinical data with nephrologists. This is critical, as successful launches often hinge on strong medical community support. In 2024, medical affairs spending accounted for roughly 15% of pharmaceutical marketing budgets. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePresentations at Medical Conferences\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAkebia strategically uses presentations at medical conferences to showcase vadadustat's clinical data. They target nephrologists and healthcare providers, using events like the American Society of Nephrology Kidney Week. This approach aims to educate these professionals on the drug's safety and effectiveness. In 2024, Akebia allocated $20 million to marketing, including conference presence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInvestor Communications and Events\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAkebia's investor communications and events are crucial for sharing updates. The company uses financial results, conference calls, and investor presentations. These channels highlight progress and Vafseo's potential. For instance, in Q1 2024, Akebia reported a net loss of $74.6 million. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eInvestor conferences provide direct engagement opportunities.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eFinancial results announcements keep investors informed.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eConference calls offer detailed explanations.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThese efforts aim to build investor confidence.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollaborative Clinical Trials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAkebia's initiation of collaborative clinical trials, such as the VOICE trial with U.S. Renal Care, is a key element of its promotional strategy. These trials generate real-world evidence and deepen understanding of Vafseo's safety and efficacy. This approach strategically promotes Vafseo within the medical community, supporting its acceptance and adoption. The estimated market for chronic kidney disease therapeutics is projected to reach $28.8 billion by 2029. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eVOICE trial aims to enroll approximately 1,000 patients.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eCollaboration with U.S. Renal Care expands patient access.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eReal-world data enhances Vafseo's market position.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBoosting Confidence: Marketing \u0026amp; Clinical Data\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAkebia's promotion strategies involve focused engagement and clinical data sharing, targeting nephrologists and investors. This includes detailing the drug's benefits and financial updates. Key initiatives comprise conference presence, collaborative trials, and investor communications to boost confidence and support adoption. 2024 marketing spend was about $20 million.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eStrategy\u003c\/th\u003e\n\u003cth\u003eFocus\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical Affairs\u003c\/td\u003e\n\u003ctd\u003eClinical data \u0026amp; protocols\u003c\/td\u003e\n\u003ctd\u003eCommunity support\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConference Presence\u003c\/td\u003e\n\u003ctd\u003eNephrologists \u0026amp; HCPs\u003c\/td\u003e\n\u003ctd\u003eEducation, market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInvestor Relations\u003c\/td\u003e\n\u003ctd\u003eFinancial updates\u003c\/td\u003e\n\u003ctd\u003eInvestor confidence\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003erice\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWholesale Acquisition Cost (WAC)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAkebia's Vafseo has a WAC of $1,278 for a 30-day supply, roughly $15,500 annually. This price is before any discounts or rebates. Pricing strategies significantly impact market access and patient affordability. As of late 2024, pharmaceutical pricing remains a key industry focus.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTransitional Drug Add-on Payment Adjustment (TDAPA)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVafseo's eligibility for the Transitional Drug Add-on Payment Adjustment (TDAPA) from CMS, effective January 2025, is a key element. TDAPA streamlines reimbursement in dialysis centers, boosting market accessibility. This means providers receive extra payments, easing the financial burden. This supports Vafseo's competitive edge. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContracting with Dialysis Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAkebia's Vafseo sales strategy heavily relies on contracts with dialysis organizations. These agreements involve off-invoice discounts, reducing the product's cost directly. Furthermore, volume-based tier discounts are offered based on the Wholesale Acquisition Cost (WAC) price. Such contracts aim to increase market share and encourage usage within dialysis centers. In 2024, the dialysis market represented a significant portion of pharmaceutical sales, with similar contracting strategies being common.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsideration of Non-Dialysis Population Potential\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAkebia's pricing strategy for Vafseo, reflected in its WAC pricing, considered the potential for label expansion into the non-dialysis patient population. This strategic move indicates a forward-thinking approach to capture a larger market share. The company likely anticipated increased revenue streams from this broader patient base. This approach is crucial for long-term financial sustainability and growth. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eVafseo's WAC pricing reflects a focus on market penetration.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eExpanding into non-dialysis patients could substantially increase revenue.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThis strategy is crucial for sustained financial health.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoyalty Payments on Net Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAkebia's pricing strategy includes royalty payments to CSL Vifor based on Vafseo's U.S. net sales. This tiered royalty structure directly affects Akebia's net revenue, representing a significant cost component. The royalty rates fluctuate based on the sales volume achieved, influencing profitability. These payments are a crucial factor in financial planning and forecasting for Akebia. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eRoyalty payments are tiered based on annual net sales.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThese payments impact Akebia's net revenue.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThe agreement is with CSL Vifor for Vafseo sales in the U.S.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePricing Strategy: High WAC, Strategic Discounts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAkebia strategically prices Vafseo with a high WAC ($1,278 for 30-day supply). This approach is adjusted by discounts and rebates to enhance market accessibility. Royalties paid to CSL Vifor affect net revenue; the tiered structure considers Vafseo's U.S. sales.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct orange_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePricing Factor\u003c\/th\u003e\n\u003cth\u003eDescription\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eWAC Pricing\u003c\/td\u003e\n\u003ctd\u003e$1,278\/30-day supply\u003c\/td\u003e\n\u003ctd\u003eHigh initial cost.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiscounts\/Rebates\u003c\/td\u003e\n\u003ctd\u003eOff-invoice, volume-based\u003c\/td\u003e\n\u003ctd\u003eIncreases market share.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalties\u003c\/td\u003e\n\u003ctd\u003eTiered to U.S. net sales\u003c\/td\u003e\n\u003ctd\u003eInfluences profitability.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003ch2\u003e4P's Marketing Mix Analysis \u003cspan style=\"color: #FB9C46;\"\u003eData Sources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003cp\u003eOur 4Ps analysis of Akebia relies on SEC filings, earnings calls, press releases, and clinical trial data.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Data-Sources.svg\" alt=\"Data Sources\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"SAE","offers":[{"title":"Default Title","offer_id":55926461858176,"sku":"akebia-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0899\/6510\/1440\/files\/akebia-marketing-mix.png?v=1746107169","url":"https:\/\/swotanalysistemplates.com\/products\/akebia-marketing-mix","provider":"SWOT Analysis Templates","version":"1.0","type":"link"}